13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04086225
(ClinicalTrials.gov)
January 17, 20199/9/2019Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).Relapsing Multiple Sclerosis (RMS)Drug: Cladribine;Drug: Placebo;Drug: Microgynon®Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNULLRecruiting18 Years45 YearsFemale34Phase 1Germany;Poland
2NCT03745144
(ClinicalTrials.gov)
January 17, 201914/11/2018Effects of Cladribine Tablets on the PK of Microgynon®A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMSRelapsing Multiple Sclerosis (RMS)Drug: Cladribine;Drug: Placebo;Drug: Microgynon®Merck KGaA, Darmstadt, GermanyNULLActive, not recruiting18 Years45 YearsFemale24Phase 1Germany;Poland
3EUCTR2014-005129-10-FI
(EUCTR)
27/01/201512/12/2014Multiple Sclerosis, menopause and hormone replacement therapyMultiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis Multiple sclerosis
MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852
MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Femoston 2/10
Product Name: Femoston 2/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Trade Name: Femoston 1/10
Product Name: Femoston 1/10
INN or Proposed INN: ESTRADIOL HEMIHYDRATE
INN or Proposed INN: DYDROGESTERONE
Irina ElovaaraNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
Finland
4EUCTR2006-005460-30-IT
(EUCTR)
22/05/200727/10/2008POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUSPOPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS Multiple Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: DEMESTRIL SEPTEM
INN or Proposed INN: Estradiol
Trade Name: LUTENYL
INN or Proposed INN: Nomegestrol
OSPEDALI CIVILI DI LIONENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
300Italy
5NCT00127075
(ClinicalTrials.gov)
June 20054/8/2005POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple SclerosisPOPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple SclerosisMultiple SclerosisDrug: nomegestrol acetate;Drug: estradiol;Drug: placeboHospices Civils de LyonNULLActive, not recruiting18 Years50 YearsFemale300Phase 3France